Rabies Virus: Pathogenesis and Immune Response

Introduction to Rabies Virus

Rabies is a fatal zoonotic disease caused by viruses of the genus Lyssavirus, with classical rabies virus (RABV) responsible for nearly all human infections. Transmission occurs primarily through the bite of infected mammals, especially domestic dogs, which serve as the main reservoir in endemic regions. Despite effective vaccines, rabies remains a significant public health concern due to gaps in vaccination and post-exposure prophylaxis.

• Rabies Virus (RABV): Neurotropic virus causing lethal encephalitis.

• Transmission: Typically via bites from infected animals.

• Reservoirs: Domestic dogs in Africa and Asia.

• Vaccine Availability: Highly effective, but underutilized in some regions.

• Annual Deaths: Tens of thousands globally.

Pathogenesis and Immune Evasion

After peripheral introduction, RABV rapidly enters peripheral nerves and travels retrogradely to the central nervous system (CNS), causing lethal encephalitis. The virus exhibits minimal replication at the inoculation site and induces a weak immune response in peripheral tissues.

• Neurotropism: Virus targets neural tissues, leading to CNS infection.

• Immune Evasion: RABV suppresses both innate and adaptive immune responses.

• Viral Proteins:

  • Phosphoprotein (P): Antagonizes type I interferon signaling by sequestering STAT1/STAT2.

  • Matrix (M) Protein: Interferes with host mRNA export.

  • Nucleoprotein (N): Shields viral RNA from RIG-I–like receptor recognition.

• Immune Activation: Attenuated/vaccine strains elicit stronger immune responses than wild-type viruses.

Example: Attenuated SADP.5 strain induces robust germinal center (GC) responses and virus-neutralizing antibodies (VNAs), unlike wild-type SHBRABV.

Experimental Approach: Mouse Models of Rabies Infection

Study Objectives and Hypotheses

The study aims to dissect the mechanisms of immune activation and evasion in rabies virus infection using controlled mouse models. The central hypothesis is that survival correlates with timely and coordinated adaptive immune responses, while lethal infection is associated with impaired immunity and high CNS viral burden.

• Survival: Linked to virus-neutralizing antibodies, antiviral cytokines, and organized GC responses.

• Lethal Infection: Associated with weak/delayed humoral immunity, dysregulated cytokines, impaired lymphoid activation, and high neural viral antigen.

Research Questions

• Humoral Response (VNT): Do survivors have measurable VNA titers? Is there a correlation between VNA titers, survival, and CNS viral burden?

• Cytokine Profile: What systemic cytokine patterns are observed in survivors vs non-survivors? Which cytokines correlate with high VNA titers and good outcomes?

• Tissue-Level Mapping: How does lymphoid architecture differ between survivors and non-survivors? Is there a relationship between GC activity, VNA titers, and cytokine profiles?

Experimental Design and Measurements

Stepwise Analysis

Virus Neutralization Tests (VNT)

VNTs are used to measure the presence and magnitude of virus-neutralizing antibodies in survivors and non-survivors across different strains and doses.

• SHBRABV Survivors: Long-term (28 days) and medium-term (15 days) survivors tested for VNA titers.

• DogRABV Survivors: Dose-response comparison at 14 days.

• SADP.5 Survivors: Attenuated strain used as a benchmark for strong immunity.

Cytokine Measurements

Cytokine profiles are assessed using LEGENDplex panels to distinguish Th1/Th2 and antiviral responses in survivors and non-survivors.

• Th1/Th2 Panel (8-plex): IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IFN-γ, TNF-α

• Anti-Virus Response Panel (13-plex): IFN-γ, CXCL1, TNF-α, CCL2, IL-12p70, CCL5, IL-1β, CXCL10, GM-CSF, IL-10, IFN-β, IFN-α, IL-6

• Expected Outcomes:

  • SADP.5: Balanced antiviral and Th1/Th2 signal

  • SHBRABV high-VNA survivors: Moderate–strong similar pattern

  • Low-VNA survivors/non-survivors: Weaker or dysregulated cytokine responses

Immunohistochemistry (IHC) and Immunofluorescence (IF)

Tissue-level mapping is performed to assess immune architecture and viral antigen distribution.

• CNS Axis: Brain, spinal cord, trigeminal ganglion

• Lymphoid Organs: Draining lymph nodes, spleen

• Entry Tissues: Muscle at inoculation site

Antibody Panels

• Humoral Immune Architecture: B220, GL7, PNA, BCL6, Ki67, CD138, IgG, IgM

• T Cell and APC Support: CD3, CD4, CD8, PD-1, MHC-II, CD11c

• Innate Antiviral and Myeloid Activation: IBA1, CD68, CD11b, MHC-II

Comparative Outcomes and Correlations

• VNA Titer: Correlates with GC activation and survival.

• Cytokine Profile: Matches "activated" GC structure in survivors.

• Viral Antigen Distribution: Higher in CNS tissues of non-survivors.

• Strain Comparison: SHBRABV vs DogRABV vs SADP.5 (attenuated).

• Lymphoid Architecture: Collapse in non-survivors vs preservation in survivors.

Tables: Experimental Cohorts and Outcomes

Table 1: Long-Term Survivors of SHBRABV Infection

Table 2: Medium-Term Survivors of SHBRABV Infection

Table 3: Non-Survivors of SHBRABV Infection

Table 4: Survivors and Non-Survivors of DogRABV

Table 5: SADP.5 Infected Animals for Baseline Reference

Summary and Academic Context

• Rabies Virus Infection: Demonstrates complex immune evasion strategies, leading to variable outcomes in mouse models.

• Adaptive Immunity: Timely and organized responses (VNAs, cytokines, GC formation) are critical for survival.

• Experimental Models: Allow dissection of immune mechanisms and comparison of pathogenic vs attenuated strains.

• Applications: Insights may guide improved post-exposure prophylaxis and vaccine strategies.

Additional info: The notes expand on the original content by providing definitions, context for immune mechanisms, and structured tables for comparison. The experimental design and immunological assays are described in detail to aid understanding for microbiology students.